Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors

US8906374B2 · kind B2 · utility

Assignee

• Cedars Sinai Medical Center · US

Inventors

• Hyung Kim · Los Angeles, US
• Yanping Wang · Beijing, CN

Key dates

• Filing date: Apr 20, 2011
• Grant date: Dec 9, 2014
• Expiry date: Jun 3, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/24
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides methods for treating a malignant neoplastic cell proliferative disorder or disease, comprising administering to a subject in need thereof an effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent. Such methods find utility in the treatment of certain subsets of malignant neoplastic cell proliferative disorders or diseases, e.g. renal cell carcinoma and melanoma. The invention also provides for pharmaceutical compositions comprising a therapeutically effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent in a pharmaceutically acceptable carrier.